A quorum was present and Dr. Reinhard Walter, Chair, presided over the CHM6 EC face-to-face meeting. The following is a summary of the actions and key discussion topics that impacted the work of the CHM6 EC, grouped by topic.

1. **Closed Sessions (held at the start of the meeting):** EC members discussed the following topic in closed sessions: conflict of interest (CoI) review.

2. **OTC Drug Products Working Group Update:** EC members received an update on the CHPA-FDA-USP Roundtable Retreat held October 29, 2018. Work of the OTC Drug Products Working Group, key concepts and challenges were discussed.

3. **USP-FDA Collaboration:** USP staff updated EC members on the collaborative work of USP and FDA in the development of documentary standards for Acetaminophen and Diphenhydramine Hydrochloride Tablets.

4. **FDA Regulatory Pharmaceutical Analysis:** FDA provided an overview of its regulatory process for pharmaceutical analysis.

5. **CHM6 EC Work Plan—Metrics to Date and Next Steps:** USP staff gave an overview of the metrics to date of the work of the CHM6 EC. An update was also provided on the CHM6 work plan and what activities would be undertaken for the last 2 years of the 2015–2020 cycle.

6. **Conflict of Interest:** EC members discussed CoIs and their potential impact on the future work of the CHM6 EC. USP legal staff provided a broad overview of CoIs and guidance.

7. **Valsartan Case Study:** EC members were provided detailed background on the Valsartan case, lessons learned, and next steps.

8. **Reference Standard (RS) Development:** USP staff provided EC members and overview of RS development.

9. **Performance Tests:** USP staff updated EC members on historical perspectives, strategy, dissolution, disintegration, and drug release tests in USP monographs.

10. **General Chapter Revisions:** EC members received a status update on General Chapter <476> Control of Organic Impurities in Drug Substances and Drug Products and <1086> Impurities in Drug Substances and Drug Products.

11. **Chlorpheniramine Maleate and Its Organic Impurities:** USP staff shared USP’s proposed method for analyzing Chlorpheniramine Maleate and its organic impurities in OTC and extended-release tablets using Silica Hydride HPLC columns.

12. **Collaborative Work with Instrument Manufacturers for Inorganic Monograph Modernization:** USP staff updated EC members on the progress to date of this project, whose goal is to bring outdated titration procedures up to date.